DNLI vs. VCEL, KYMR, CGON, BEAM, DNA, TWST, FUSN, RXRX, SANA, and IMCR
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Vericel (VCEL), Kymera Therapeutics (KYMR), CG Oncology (CGON), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), Twist Bioscience (TWST), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.
92.9% of Denali Therapeutics shares are held by institutional investors. 5.2% of Vericel shares are held by company insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Vericel has higher earnings, but lower revenue than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vericel had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Vericel and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.95 beat Vericel's score of -0.49 indicating that Vericel is being referred to more favorably in the media.
Denali Therapeutics received 103 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 67.38% of users gave Denali Therapeutics an outperform vote while only 62.38% of users gave Vericel an outperform vote.
Vericel has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
Vericel currently has a consensus price target of $46.40, indicating a potential upside of 0.76%. Denali Therapeutics has a consensus price target of $41.22, indicating a potential upside of 167.16%. Given Vericel's higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Vericel.
Vericel has a net margin of -1.61% compared to Vericel's net margin of -36.51%. Denali Therapeutics' return on equity of -1.55% beat Vericel's return on equity.
Summary
Vericel beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
